| abstract |
The present invention relates to novel conjugates between polypeptide varian ts of pro-tein C and a non-polypeptide moiety, such as PEG or sugar moieties. I n particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and a1- antitrypsin. Consequently, such conjugates have an increased in vivo half- life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septi c shock. |